Iodine-123 Metiodobenzylguanidine (MIBG) imaging for selection heart failure patients eligible to an implantable automatic defibrillator (ICD) in primary prevention

26 May 2018 (00:00 - 00:00)

Organised by:

About the speaker

Doctor Chahinez Ketfi

Hospital Bichat-Claude Bernard, Paris (France)

61 More presentations in this session

Presentation thumbnail

Real-world patterns of loop diuretics dose adjustment and association with outcomes in outpatients with chronic heart failure: observations from the ESC Heart Failure Long-Term Registry

Doctor C. Kapelios (Athens, GR)

Abstract Slides

Presentation thumbnail

Acute kidney failure and hyperkalaemia in patients with chronic hearth failure treated with aldosterone antagonists- a risk-benefit network meta-analysis

Presentation thumbnail

Intermittent administration of levosimendan ambulatory in patients with advanced chronic heart failure: experience in our center.

Presentation thumbnail

Sildenafil for chronic heart failure : a meta-analysis

Mrs C. Ariano (Naples, IT)

Presentation thumbnail

The dilemma of recurrent hyperkalaemia and use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: a European multi-national targeted chart review

Professor P. Rossignol (Monaco, MC)

Abstract Slides

Access the full session

Session thumbnail

Poster Session 2 - Chronic Heart Failure – Treatment

The Event

Heart Failure 2018

26 May - 29 May 2018

You may be interested in

Congress Presentation

Implantable cardioverter-defibrillator

Congress Presentation

The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?

Congress Session

Debate on primary prevention in ICD therapy

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources